Reason for request
Inclusion on the list of medicines approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit is substantial. |
Clinical Added Value
| important |
In view of the results obtained in a population with an unfavourable prognosis and the size of the effect observed, the Transparency Committee considers that TORISEL provides a substantial improvement in actual benefit (IAB level II) compared with interferon alpha (ROFERON-A) in advanced renal cell carcinoma patients with at least 3 of the 6 prognostic risk factors. |
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
RvGFJ4teU2X5Jpwr
